Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3496 ↗At a glance
Journal article in Clinical Pharmacology & Therapeutics, 2025. Written by Michikazu Nakai and 9 co-authors. Institution: Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Japan. Major MEDLINE topics: Heart Failure, Atrial Fibrillation, Adrenergic beta-Antagonists. 31 references. Funded by: Labor Research Grants from the Ministry of Health, Labour and Welfare of Japan, JSPS KAKENHI.
Topics: Herzinsuffizienz
Abstract (original language)
Evidence of the effectiveness of β‐blockers in heart failure (HF) and atrial fibrillation (AF) in a contemporary cohort is controversial. This study investigated the association between the use of β‐blockers and prognosis in hospitalized HF patients with and without AF in Japan. Patients hospitalized with the first episode of acute HF were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan between April 2014 and March 2021. Associations of β‐blocker use and prognosis were compared by propensity score matching among the AF or non‐AF group. A mixed‐effects survival model was used, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Among 428,650 patients discharged with HF in 4,433 hospitals, 175,174 (40.9%) were ≥ 85 years old, 151,873 (35.4%) had complicated AF, and 236,457 (55.2%) were β‐blocker users. In a matched AF group, β‐blocker use was associated with a lower composite outcome of all‐cause mortality or HF rehospitalization (HR [95% CI], 0.95 [0.93–0.97]). A similar result was obtained in a matched non‐AF group (0.95 [0.94–0.96]). In addition, the HRs in patients aged ≥ 85 years and female patients were 1.00 [0.98–1.02] and 1.01 [0.98–1.03] in the AF group and 1.03 [1.01–1.05] and 0.98 [0.97–1.00] in the non‐AF group, respectively. The favorable prognostic associations of β‐blocker use were observed regardless of AF in patients across a broad spectrum of HF in a superaged society.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Japan.
- Clinical Research Support Center, University of Miyazaki Hospital, Miyazaki, Japan.
- Department of Cardiology, Sakurabashi Watanabe Advanced Healthcare Hospital, Osaka, Japan.
- Department of Public Health, Health Management and Policy, Nara Medical University, Kashihara, Japan.
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Transformative System for Medical Information, Osaka University Graduate School of Medicine, Suita, Japan.
ORCID profiles: Michikazu Nakai, Yoshitaka Iwanaga, Koshiro Kanaoka, Yoko Sumita, Yuichi Nishioka, Tomoya Myojin, Katsuki Okada, Tatsuya Noda, Tomoaki Imamura, Yoshihiro Miyamoto
Funding
- Labor Research Grants from the Ministry of Health, Labour and Welfare of Japan
- JSPS KAKENHI
Cite
APA
Nakai, M., Iwanaga, Y., Kanaoka, K., Sumita, Y., Nishioka, Y., Myojin, T., Okada, K., Noda, T., Imamura, T., & Miyamoto, Y. (2025). Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3496
Vancouver
Nakai M, Iwanaga Y, Kanaoka K, Sumita Y, Nishioka Y, Myojin T, et al. Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3496
BibTeX
@article{Nakai2025,
author = {Nakai, Michikazu and Iwanaga, Yoshitaka and Kanaoka, Koshiro and Sumita, Yoko and Nishioka, Yuichi and Myojin, Tomoya and Okada, Katsuki and Noda, Tatsuya and Imamura, Tomoaki and Miyamoto, Yoshihiro},
title = {Contemporary Use of β‐Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3496}
}
EUVIMED